Latest news with #Galvin
News.com.au
11 hours ago
- Sport
- News.com.au
‘Tried to make him better': Luai opens up on Galvin exit as Tigers star makes huge contract call
Tigers skipper Jarome Luai has opened up on facing Lachlan Galvin for the first time since his defection to the Bulldogs. Luai and Galvin reportedly had a frosty relationship as teammates, even before Galvin's decision to leave the club. FOX LEAGUE, available on Kayo Sports, is the only place to watch every game of every round in the 2025 NRL Telstra Premiership, LIVE with no ad-breaks during play. New to Kayo? Get your first month for just $1. Limited-time offer > Luai was vocal in defending coach Benji Marshall after his coaching credentials were called into question by Galvin's management as one of the reasons he wanted to leave the club. However, Luai told The Daily Telegraph there was no hard feelings between the pair and maintains they had a good relationship at the Tigers. 'I think he spoke about it already and said that there wasn't any beef in the relationship, which is true,' Luai told The Daily Telegraph. 'I did my best to try and make him a better footballer. 'All pre-season I thought to myself, we connected well and you know, we started the year off in great form, won some games. 'But like I just said before, he made a call on his future. All the other best of him, bro. I'm just focused on my career.' Luai refused to get caught up in the hype of playing against Galvin and is more focused on bouncing back from a loss to the Panthers. 'It's not about Lachie, it's not about the Dogs - it's about us,' Luai told WWOS. 'That's a story everyone wants to talk about. For us here inside our four walls, it's about us and how we perform on game day. Coming off the back of a loss, my main focus as a player is how I prepare throughout the week and ultimately, how I'm gonna perform. 'It's all about me and my team.' Luai also all but confirmed he will see out the remainder of his Wests Tigers deal, despite get-out clauses giving him the option to walk out on the club mid-contract. Luai's $6 million deal has been in the spotlight since he was critical of Lachlan Galvin walking out on the Tigers, despite the fact he had contract clauses that would allow him to do the same. The Tigers' skipper's five-year deal has options in his favour that would allow him to leave at some point in the final three years of the deal from 2027. It means Luai could become available to negotiate with rival clubs for 2027 from November 1 this year. When questioned about the clauses by Channel 9's Danny Weidler on WWOS, Luai moved to end speculation he would leave the club. 'Scoops? Nah, just scoops of ice cream,' Luai joked. 'I'm staying, don't worry - for life. 'I think when things get hard, people are sort of expecting you to change and I'm not that type of guy. I'm here for the long run and I'm here to change this club around.' The Tigers recently re-signed co-captain Api Koroisau to a two-year extension through until the end of 2028, meaning his contract length is similar to Luai's which expires in 2029. Luai admitted the chance to keep playing with Koroisau was a big factor in him committing to the Tigers. 'He's a big part of this club and a big reason why I signed here,' Luai said. 'It's good to see the skip locked in for a few more years, I can't wait to play some more footy with him.'
Yahoo
12 hours ago
- Sport
- Yahoo
'Still dirty': Tigers fans issue warning to Lachie Galvin for Bulldogs grudge match
Wests Tigers fans have promised to bring the heat when Lachie Galvin runs out for the first time against the club he ditched mid-season. But they risk being drowned out by the rabid Bulldogs Army. The 20-year-old playmaker will line-up against the Tigers at CommBank Stadium on Sunday afternoon and can expect a serve from the home crowd with every touch of the ball. David Craine is a lifelong Balmain/Wests Tigers fan and administers the 'Wests Tigers Will Never Die' Facebook page, which has more than 44,000 members. He predicts Galvin will cop a hostile reception from both fans and former teammates. "The fans are still dirty over him walking out and will let him know. They will boo him at every opportunity," Craine told Yahoo Sport Australia. "And I believe it won't just be the fans - the players will be filthy as well. "I've heard reports that the team want payback for what he said about Benji…basically saying he can't coach. These players are only there because they believe in Benji. They will want to send him (Galvin) a strong message." But for all the passion and anger Tigers fans will muster, Craine concedes they face a tough time being heard over the raucous Bulldogs Army. Canterbury's fan base is on the march and turning up in big numbers during the club's best season in a decade. RELATED: Storm ace lifts lid on wife detail after turning back on big-money switch Hunt responds after Slater's criticism of Broncos as NRL feat looms Knights extend Origin hero amid fan uproar over baffling saga Lachie Galvin already making an impression at the Bulldogs Galvin has won them over in recent weeks and can expect plenty of support from the blue and white corner. "I expect Dogs fans to be bigger and louder than our sobbing fans," Craine predicted. "Their fans are the most passionate and noisy in the game and will try to drown the Tigers fans out. But we won't back down and they won't back down. We'll both be doing what we can to give our side an edge. It's all set up for a really feisty afternoon with plenty at stake for both teams." Canterbury has kept Galvin out of the firing line this week, refusing to offer him up to media outlets for fear of heightening tensions. It's been left to teammates to speculate on how the rookie half will handle playing against the club he rejected two months ago. Halves partner Matt Burton said: "He'll just go to another level and get better from that (scrutiny). That won't faze him at all. "There's going to be a lot of talk, but whatever's in these four walls, we just stick together and we don't worry about that. It's like he's a 26-year-old in a 20-year-old's body. He's got that maturity about him."
NDTV
21-07-2025
- General
- NDTV
Gen Z Stare: All About The Viral Trend That Has Generations Talking
A new trend dubbed the "Gen Z stare" is sparking debate across social media and the workplace. Characterised by a long, blank, expressionless gaze in a variety of social situations, the look has gone viral through videos on TikTok and is being widely discussed - both humorously and seriously - across generations. According to ABC News, the stare is often seen in response to casual greetings or workplace queries, leaving older generations puzzled or even frustrated. Critics often assail the stare, making snap judgments about what it means: boredom, indifference, superiority, judgment or just sheer silliness - even a death stare. "A lot of Gen Z folks are saying, 'Sorry, this is just the way we talk,' while others say this is more specific to customer service," said Brad Mielke, host of ABC 's Start Here podcast. Mielke added that even Gen Z workers are noticing it in their peers. "You even have Gen Z-ers sort of noticing this in each other," he said, calling the moment a rare instance of self-reflection for the hyper-online generation. But others argue it goes beyond facial expression. In an article for Forbes, author Bryan Robinson warns against jumping to conclusions. Robinson said he spoke to Vintage's chief research officer Joe Galvin who told him, "The 'Gen Z stare' is more than just a viral buzzword. Similar to past trends such as 'quiet quitting', it is a pervasive one, highlighting a larger issue in today's workplace: A growing generational disconnect in employee communication and expectations." The stare, Galvin notes, can be misinterpreted as disinterest or defiance, but it may stem from Gen Z's lack of exposure to real-world social interaction - particularly during the pandemic, when screens replaced face-to-face communication. In some cases, experts liken the frozen expression to a trauma "freeze" response, reflecting stress or uncertainty rather than disrespect. As generational differences come under the spotlight, workplace leaders are being urged to rethink how they assess engagement. "Are team members truly disengaged, or are leaders relying on outdated ideas of what attentiveness and participation should look like?" Galvin asked. "Misreading body language can lead to confusion, frustration, and missed opportunities to connect." The trend follows other generational behaviours like the "millennial pause" and baby boomers - those born between 1946 and 1964 - signing texts like letters. As Mielke noted on ABC News, "We've all got them... This is the first time Gen Z is under fire from the rest of the generations." Whether a fleeting fad or a sign of deeper disconnect, the Gen Z stare is forcing a wider conversation on social media about how we read - and misread - each other in the modern workplace.
Courier-Mail
20-07-2025
- Sport
- Courier-Mail
NRL 2025: Lachlan Galvin opens up on his move to the Bulldogs after starring at halfback
Don't miss out on the headlines from NRL. Followed categories will be added to My News. Lachlan Galvin is aware of the criticism that's followed his mid-season move to the Bulldogs, but he insists it won't affect him after he celebrated his move to halfback by throwing what his coach described as one of the 'bravest' passes he's seen to lift his side to a dramatic win over the Dragons. His move from the Wests Tigers dominated the news cycle, and it hasn't stopped since he arrived at Belmore with everyone fascinated by how Cameron Ciraldo would use him. He's started games on the bench, at five-eighth and even dropped out of the 17, but Galvin will be Canterbury's halfback for the rest of the year after showing signs that he is the trump card they've been missing in attack. He scored a try in the first half after he backed up a big break by Stephen Crichton, but it's what he did with the game on the line that justified the move to bring him in. With his side struggling to land the killer blow, Galvin drifted to the edge, waited for Tyrell Sloan to make a decision in defence and then fired a long ball over the top to rookie Jethro Rinakama to score the winner in the corner. 'Natural instincts kicked in and I saw him come up and I just threw it,' he said after the game. 'No pressure (because) I put the work in at training, 'Ciro' and all the coaching staff and the boys have put trust in me. I'm always confident going out there. When I see it, I'm just going to throw it. 'I just saw it and took it, that's pretty much what I do. I saw the pass and I threw it. I'm always going to do that, I'm always going to back my instinct. That's just me. 'I just saw (Sloan) come out pretty early. He'd done it a few times before with kicks at the back. I thought I might as well just throw it. Lucky it paid off.' The pass could have easily been intercepted but Galvin didn't hesitate with the game on the line. 'To make that play at the end, it's possibly one of the bravest passes I've seen,' Ciraldo said, revealing Galvin had done more than enough to keep the No.7 jersey before he nailed the crucial play. 'We all know he's had pressure on him, so I can't rap him enough for how well he's handled it. 'To trust his instincts and to trust himself to make that play just shows everyone what we've been seeing for the past six weeks.' Lachlan Galvin and Matt Burton have seven weeks to build their combination heading into the finals. Picture:His position in the team and the effect it's had on other players has been questioned, with fellow spine members Reed Mahoney and Toby Sexton set to leave the club at the end of the year. Mahoney scored a try on Saturday night while Sexton played well in NSW Cup, with Galvin adamant the outside noise isn't getting to him as he looks to spend the next seven weeks developing his combination with halves partner Matt Burton. 'It is what it is, people are always going to have their opinions but I'm just going to keep working,' he said. 'I listen to the people inside the four walls at Belmore and that's Ciro and all the coaches and all the boys. I keep working hard and for it to pay off tonight and me to keep building for the rest of the year, that's all I'm going to do. 'I'm just here to learn. That's all I want to do. I'm only 20 years of age, I just want to keep building. I'll just keep learning and keep building. Ciro and all the assistants are doing that for me. '(Burton) is mad to play with, he's got such a strong running game so I'm just trying to free up space for him to use that. 'What I can do for him to get him the ball and get the strike players in our team the ball, that's what I'm going to do. I love playing with him. We're building a good bond now. He's real good out on the field. He talks well. I love him.' Crichton was impressed with what he saw from the 20-year-old and praised him for how he's handled a turbulent few months. 'He's been copping a lot ever since he came to the club, but we see in our four walls what he does at training,' he said. 'The confidence for him to throw that pass shows what type of player he is. We're happy he's at our club.' Originally published as 'One of the bravest passes I've seen': Lachlan Galvin breaks down his match-winning play, opens up on the pressure since joining the Bulldogs
Yahoo
16-07-2025
- Health
- Yahoo
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive clinical and biomarker effects of zervimesine in the low p-tau217 population in Phase 2 Alzheimer's disease study - PURCHASE, N.Y., July 16, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that James E. Galvin, MD, MPH will present results from the Phase 2 'SHIMMER' study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the Alzheimer's Association International Conference (AAIC). Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the COG1201 SHIMMER study (NCT05225415) director. The presentation will take place on July 29, 2025 in the 8:00 a.m. ET Featured Research Session. 'The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease,' stated Dr. Galvin. 'My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB.' DLB is the second most common cause of dementia, affecting approximately 1.4 million Americans. People living with DLB experience a variety of symptoms, which typically include neuropsychiatric features such as hallucinations, delusions and agitation; cognitive impairment; Parkinsonian movement disorders; REM sleep behavior disorder; and fluctuations in attention and awareness. Currently no disease-modifying therapeutics are approved for DLB. Anthony Caggiano, MD, PhD, Cognition's CMO and head of R&D added, 'Zervimesine's broad neuroprotective mechanism is illustrated by the favorable results observed in the Phase 2 SHIMMER study in DLB. In the SHIMMER study, zervimesine treatment slowed the progression of DLB's diverse symptomology, with a meaningful impact on neuropsychiatric, motor, functional, and cognitive measures. Results from the Phase 2 'SHINE' study in people with Alzheimer's disease add further evidence to zervimesine's neuroprotective properties. We look forward to presenting results from both studies at AAIC.' The SHINE study was a signal-finding trial that showed zervimesine treatment preserved cognitive and functional abilities better than placebo in people with mild-to-moderate Alzheimer's disease. This impact was more robust in participants with lower levels of p-Tau217, who experienced a 95% slowing of cognitive decline at six months as measured by ADAS-Cog 11 compared to placebo. Cognition will present clinical efficacy results and new proteomic findings from this Alzheimer's study at AAIC. Dr. Galvin's slide presentation as well as Cognition's three posters will be available on the Cognition Therapeutics website in accordance with the conference's embargo policy. Cognition at AAIC: Featured Research Session: • Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812): 8:00-8:45 a.m. on July 29 Posters: • Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum: (#106858) July 27 • Exploratory CSF proteomic analysis of a pre-specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer's disease patients treated with zervimesine: (#102120) July 27 • An exploratory proteomics plasma biomarker analysis of the SHIMMER Phase 2 clinical trial to assess the pharmacodynamic effect of the sigma-2 receptor modulator zervimesine in dementia with Lewy bodies patients: (#106855) July 27 About the SHIMMER Study in Dementia with Lewy BodiesThe SHIMMER study (COG1201; NCT05225415) is an exploratory double-blind, placebo-controlled Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB, who were randomized to either daily oral doses of zervimesine (100 mg or 300 mg) or placebo for six months. A total of 88 participants were randomized to the two treatment arms and 42 to the placebo arm. Assessments were conducted throughout the study using a number of tools, including the Neuropsychiatric Inventory (NPI) to measure changes in hallucinations, anxiety and delusions; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research Battery (CDR), which track cognitive performance; and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism. The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million (R01AG071643) and was conducted in collaboration with James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). About the SHINE Study in Mild-to-Moderate Alzheimer's Disease The SHINE study (NCT03507790) is a double-blind, placebo-controlled Phase 2 signal-finding trial that enrolled 153 adults with mild-to-moderate Alzheimer's disease who were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. The primary endpoint was safety and tolerability. The key secondary endpoint of cognition was ADAS-Cog 11. Exploratory endpoints included change in MMSE, ADAS-Cog 13, ADCS-ADL and -CGIC as well as pre-specified subgroup analyses included a comparison of cognitive and functional changes in participants with plasma p-tau217 levels above and below the median. The SHINE study was supported by two grant awards from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million. About Zervimesine (CT1812)Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer's disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person's ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer's and DLB. Zervimesine has been generally well tolerated in clinical studies to date. Zervimesine has been granted FDA Fast Track designation in Alzheimer's disease. The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812. About Cognition Therapeutics, Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study (NCT05531656) in early Alzheimer's disease. We believe zervimesine and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our future clinical development plans, and statements regarding our clinical trials of zervimesine and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information:Cognition Therapeutics, Casey McDonald (media)Tiberend Strategic Advisors, Mike Moyer (investors)LifeSci Advisorsmmoyer@ This press release was published by a CLEAR® Verified individual.
